GAD-7

A brief seven-item questionnaire measuring anxiety symptom severity over the past two weeks. Widely used for screening, case finding, and monitoring treatment response for generalised anxiety and related conditions.

Specialties: general_practice, psychiatry

Time:2 min
Pages:1
Questions:7
Free

One Time Calculator

Get instant validated scores or print a PDF version

Example Assessment Result

GAD-7 - Generalized Anxiety Disorder 7-item scale

Total Score
10/21
SeverityModerate Anxiety
7 Questions
Completed
Premium

Track Over Time

Prove your procedures help patients with outcome data

TimingBaseline
Date15 Jan 2024

GAD-7 Total Score14/21
Anxiety severityModerate
30-Day Money-Back Guarantee

Free setup for clinics and clinicians

About the GAD-7

The GAD-7 is a short, self-administered questionnaire that takes about two minutes to complete. It is suitable for primary care, specialist mental health services, and research. Scores help clinicians identify patients who may benefit from further assessment or intervention for anxiety. The measure has strong psychometric properties and performs well as a screening tool alongside clinical judgement.

Prevalence:
common

Medical Specialties

General Practice
Psychiatry

Clinical Indications

Generalised Anxiety Disorder
Anxiety
Anxiety Symptoms
Mental Health Screening
Stress
Panic Disorder
Social Anxiety

Developer Information

The GAD-7 was developed by Drs. Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, and Bernd Löwe, building on the Patient Health Questionnaire family. It was first published in 2006.

Copyright & Licensing

The GAD-7 is widely reproduced for clinical and research use (including by organisations such as AHRQ and NHS England). Usage terms may vary by setting; confirm local copyright and licensing requirements for commercial or adapted materials.

Administration Instructions

Over the last 2 weeks, how often have you been bothered by any of the following problems?

Scoring Methodology

Each of the seven items is scored from 0 (Not at all) to 3 (Nearly every day). The total score is the sum of all item scores, ranging from 0 to 21. All items are weighted equally; there are no subscales. The questionnaire refers to symptoms experienced over the last two weeks.

Scoring:
Lower is better

Meaningful Change Threshold

A change of approximately 4-5 points on the GAD-7 total score is often considered clinically meaningful, though exact thresholds vary by study population and context.

Score Interpretation

Understanding what your score means

minimal

0 - 4

Minimal anxiety - Patient reports few or no anxiety symptoms in the past two weeks.

mild

5 - 9

Mild anxiety - Some symptoms present; consider monitoring, psychoeducation, or brief interventions.

moderate

10 - 14

Moderate anxiety - Significant symptoms; further assessment and treatment planning are appropriate.

severe

15 - 21

Severe anxiety - Substantial symptom burden; active treatment and closer follow-up are typically indicated.

Subscales

This questionnaire measures multiple dimensions

Clinical Limitations & Considerations

The GAD-7 is a screening and severity measure, not a standalone diagnostic instrument. A structured clinical assessment is required to diagnose generalised anxiety disorder or other conditions. Scores reflect the past two weeks only. Cultural and language factors can affect responses; use validated translations where available. Comorbid depression or physical health problems may influence scores.

Supporting Literature

Key validation and development studies for the GAD-7

  1. 1

    A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7

    Spitzer RL, Kroenke K, Williams JBW, Löwe B

    Archives of Internal Medicine, 2006

Related Outcome Measures

Other clinical questionnaires for similar specialties and conditions

This questionnaire is provided free of charge. Patient Watch charges only for platform services (data storage, automated reminders, analytics) - not for use of clinical instruments. This non-commercial model supports academic and clinical use. View full licensing disclosure